MARKET

ACB

ACB

Aurora Cannabis
NYSE

Real-time Quotes | Nasdaq Last Sale

7.18
+0.05
+0.70%
Pre Market: 9.35 +2.17 +30.22% 07:24 11/24 EST
OPEN
7.19
PREV CLOSE
7.13
HIGH
7.43
LOW
6.96
VOLUME
2.64M
TURNOVER
--
52 WEEK HIGH
33.84
52 WEEK LOW
3.710
MARKET CAP
1.15B
P/E (TTM)
-0.2883
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Week In Cannabis: Stocks Outperform S&P, Mexico Moves Forward, Earnings, And More
Cannabis stocks outperformed the S&P 500 this week. Over the last five trading days:
Benzinga · 2d ago
Cannabis industry has 30-40% more upside, pot ETF issuer says after Joe Biden victory
Cannabis ETFs have a bright year ahead following Joe Biden's presidential win, investor Tim Seymour says.
CNBC.com · 2d ago
Cannabis Stocks Watchlist: Tilray and Canopy Growth Fall
See how Cannabis stocks performed in the market this week along with buy, hold and sell recommendations by TheStreet Quant Ratings.
TheStreet.com · 2d ago
Bears Will Win Big as It Bets Heavily Against Aurora Cannabis Stock
Investors that impulse bought cannabis stocks following the Democrats winning the U.S. Presidential elections will regret it. The mid-November spike that sent Aurora Cannabis (NYSE:ACB) did not last long. The company’s quarterly earnings report at first sent Aurora Cannabis stock above $12.00. But like clockwork, management took advantage of gullible investors by selling $150 million worth of shares. Investors who still own shares should think of selling it to get what they can.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Q1/2021 Results Lifted Aurora Cannabis On Nov. 9, the company posted revenue falling by 1% sequentially to 67.8 million CAD ($51.8 million) . This is almost flat from the prior quarter’s 67.5 million CAD of cannabis net revenue. It posted an adjusted EBITDA loss of 57.9 million CAD. The company highlighted the adjusted gross margin, before fair value adjustments, at 48%. CEO Miguel Martin once again suggested that the company is on the way to ultimately achieve positive cash flow and sustainable profitability. As shown below, Aurora failed to beat analyst expectations most of the time. It only exceeded estimates in two of the six past quarters: Surprise Type Announce Date Period End Date Actual Est. Surprise (%) EPS EPS Negative 11/9/2020 9/30/2020 ($0.64) ($0.24) -166.70% Positive 9/22/2020 6/30/2020 ($0.13) ($0.30) 56.70% Negative 5/14/2020 3/31/2020 ($0.74) ($0.53) -39.60% Negative 2/13/2020 12/31/2019 ($0.18) ($0.06) -200.00% Positive 11/14/2019 9/30/2019 $0.01 ($0.03) – Negative 5/14/2019 – ($0.08) ($0.03) -166.70% Chart courtesy of Stock Rover When it missed consensus estimates, the company tended to underwhelm by a mile. To translate, investors will have to wait longer. The Q1 results are transitional because they exclude the Nordic 1 ramp-up costs. This allowed it to post a gross margin of 52% after adjustments. Chances are high that the company will keep burning cash. To stay afloat, it will need to either sell shares or take on more debt. 7 Cyclical Stocks Still Hoping for Another Stimulus Round As of Nov. 6, Aurora had cash of approximately 250 million CAD. For the quarter ended June 2020, it had long-term debt of $217.2 million. Share Sale On Nov. 11, Aurora priced 20 million shares at $7.50, raising $150 million. The offering will not stop Aurora Cannabis stock from selling shares again in the near-term. if its EBITDA loss continues at 57.9 million CAD quarterly, then the company will burn through those funds raised in less than three quarters. After quickly selling shares not long after the stock’s rally, investors cannot trust the company. Markets acted as though Aurora did not reverse split its shares 12:1 just to keep its listing on the Nasdaq. Growth Catalyst in the U.S. CEO Martin said that potential federal action in the States could help Aurora’s business. On the conference call, he said, “We had four really important states pass comprehensive cannabis legislation, and so that starts to move the ball forward in terms of when do you get to this tipping point.” So, the CEO is speculating that the U.S. and other countries are opening up to cannabinoids containing Tetrahydrocannabinol (THC). Aurora has lots of experience working with Canadian LPs, as the federal government oversaw the manufacturing, production, packaging, and sales and marketing of cannabis. Conversely, the company faced rigorous headwinds operating in Germany, Poland, and Israel. With that experience, Aurora might have expertise in successfully expanding in the U.S. market. Fair Value and Your Takeaway Investors may assume a perpetuity growth rate of no more than 4%. In a 5-year discounted cash flow growth exit model, Aurora Cannabis stock is worth ~$3.50. Readers may use the assumptions below. The forecast assumes that Aurora will continue to struggle in growing sales in the future. Metrics Range Conclusion Discount Rate 10.5% – 9.0% 10.00% Perpetuity Growth Rate 3.5% – 4.5% 4.00% Fair Value $2.65 – $5.41 $3.46 Model courtesy of finbox Readers may click on the finbox link to change the assumptions. For example, the discount rate will fall and the growth rate will rise in a more optimistic forecast. This view would lift the fair value estimate. With that much downside risk, investors should let the market selling end before speculating on this stock. Bears have a 19.4% short position against the stock. They will stand to gain more as shares drift lower in the quarters ahead. Disclosure: On the date of publication, Chris Lau did not have (either directly or indirectly) any positions in the securities mentioned in this article.  More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets The post Bears Will Win Big as It Bets Heavily Against Aurora Cannabis Stock appeared first on InvestorPlace.
InvestorPlace · 3d ago
Why the Bull Run in Canopy Growth Will Last
InvestorPlace · 3d ago
Is This The Best Way To Play The Second Boom In Marijuana?
Hopes of nationwide legalization have triggered another rally in cannabis shares, and this time it’s all about big data, science and boosting market share
Oilprice.com · 4d ago
Tikun Olam Continues to Expand National Footprint Announces Collaboration with Pincanna to Produce Medical & Adult-Use Cannabis Products in Michigan
Tikun Olam, the global leader in medical and adult-use/wellness cannabis products, and Pincanna, Michigan's premier cannabis cultivator and distributor, have finalized an agreement to bring Tikun's world-renowned cannabis products to Michigan in Spring 2021.
PR Newswire · 4d ago
Aurora Cannabis Is Going to $0 and for 3 Good Reasons, Says Analyst
Once upon a time (way back in early 2019), Aurora Cannabis (ACB) was a dominant force in Canadian cannabis. Boasting a massive "cultivation footprint" -- hundreds of thousands of square feet of growing space producing hundreds of tons of weed per year -- Aurora controlled 20% of the mass market Canadian cannabis. And yet, Aurora could not seem to turn a profit. It lost $224 million in fiscal 2019 and then $2.4 billion in fiscal 2020.Hoping to stem the tide of these losses Aurora began focusing its efforts on selling premium marijuana blends at higher profit margins. That obviously didn't work, so in 2019 it shifted its strategy back to targeting the "value segment" -- the mass market -- which also didn't work. So lately, Aurora has begun refocusing yet again on premium blends.And how is that working out? Here's a clue: In the first quarter of its fiscal 2021 (reported last week), Aurora suffered: * a 10% decline in quarterly sales to $51 million * a net loss of $81 million * and $93 million in negative free cash flow.Sound like it might be time for another business model reset? According to GLJ Research analyst Gordon Johnson, that's exactly what's likely to happen at Aurora Cannabis. Johnson observes that when calculated in Canadian dollars, Aurora's fiscal Q1 2021 revenues of C$67.8 million actually exceeded analyst expectations for C$63.9 million. However, the company suffered an "acute bottom line-miss" when it reported losing C$0.93 -- more than twice the C$0.46 that analysts had expected it to lose. Cash burn also accelerated -- up nearly 50% sequentially to C$124.3 million.Despite this massively bad quarter, Johnson notes that the apparent electoral victory of Joe Biden as U.S. President-elect has investors betting on U.S. marijuana legalization to turn around the fortunes of the marijuana industry. So far, the month of November alone has sent Aurora Cannabis stock up nearly 73%, and in Johnson's view, there's just one way to play this marijuana stock rally:Sell. Or even, sell short \-- because this stock is going to $0, says Johnson. (To watch Johnson's track record, click here)There are at least three good reasons to follow this advice, according to the analyst. The first, obviously, is that Aurora Cannabis can't quite seem to figure out what it wants to be when it grows up -- but whatever that is, it's almost certain to be a company that loses money hand over fist. One reason for this is that the oversupply of mass market marijuana, it seems, has "recently shift[ed] to the premium segment where everyone is now focused, [such that] the high-end space [that Aurora once again favors] now has a problem," too.Even worse for all marijuana investors, though -- not just Aurora Cannabis -- Johnson thinks they're entirely misreading the legislative situation surrounding cannabis. For one thing, "US Federal nationalization" ([sic] -- pretty sure he means "legalization") -- is "highly unlikely" even under a President Biden, with the U.S. Senate still firmly in Republican hands.And second, even if marijuana legalization does get passed in the United States, "barring a change in Canadian national law," says Johnson, "ACB cannot legally operate" in the United States.Aurora Cannabis stock, it seems, just can't seem to catch a break. And at a valuation of "nearly 750x FY21E," maybe it doesn't deserve to, according to Johnson. How does Johnson's bearish stance weigh up against the word of the Street? It appears other voices are not willing to bet on cannabis player as well. Aurora Cannabis currently has a Hold consensus rating based on 12 Buys and 3 Sell. At $7.39, the average price target suggests shares will stay range bound for now. (See Aurora Cannabis stock analysis on TipRanks).To find good ideas for cannabis stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
TipRanks · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACB. Analyze the recent business situations of Aurora Cannabis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACB stock price target is 8.04 with a high estimate of 15.29 and a low estimate of 0.0000.
EPS
Institutional Holdings
Institutions: 398
Institutional Holdings: 16.90M
% Owned: 10.52%
Shares Outstanding: 160.66M
TypeInstitutionsShares
Increased
47
4.80M
New
75
-505.08K
Decreased
37
627.63K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.87%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Executive Director
Michael Singer
Chief Executive Officer/Director
Miguel Martin
Chief Financial Officer
Glen Ibbott
Chief Operating Officer
Allan Cleiren
Chief Scientific Officer
Jonathan Page
Secretary
Jillian Swainson
Lead Director/Independent Director
Ronald Funk
Independent Director
Margaret Atkins
Independent Director
Norma Beauchamp
Other
Andrea Paine
Other
Cam Battley
Independent Director
Michael Detlefsen
Independent Director
Lance Friedmann
Independent Director
Adam Szweras
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ACB
Aurora Cannabis Inc is a Canada-based medical cannabis company. The Company’s principal strategic business lines are focused on the production, distribution and sale of cannabis in Canada and internationally. The Company is focused on offering its cannabis products to global medical cannabis market, consumer use cannabis market and global hemp-derived cannabidiol (CBD) markets. The Company offers varieties of cannabis infused products under various brands that includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler and ROAR Sports. Its products portfolio includes dried cannabis, cannabis oil, soft-gels, oral dissolve strips, edibles, vaporizers and cannabis infused chocolates.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aurora Cannabis Inc stock information, including NYSE:ACB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACB stock methods without spending real money on the virtual paper trading platform.